MA30620B1 - Carboxamides substitues - Google Patents

Carboxamides substitues

Info

Publication number
MA30620B1
MA30620B1 MA31553A MA31553A MA30620B1 MA 30620 B1 MA30620 B1 MA 30620B1 MA 31553 A MA31553 A MA 31553A MA 31553 A MA31553 A MA 31553A MA 30620 B1 MA30620 B1 MA 30620B1
Authority
MA
Morocco
Prior art keywords
substituted carboxamides
substituted
carboxamides
formula
pharmaceutically acceptable
Prior art date
Application number
MA31553A
Other languages
English (en)
Inventor
Ryan Thomas Backer
Matthew Joseph Fisher
Steven Lee Kuklish
Sean Patrick Hollinshead
Edward C R Smith
Kumiko Takeuchi
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA30620B1 publication Critical patent/MA30620B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un composé de carboxamide substitué de formule I, ou un sel pharmaceutiquement acceptable de celui-ci, tel que défini dans le présent document, une composition pharmaceutique le comprenant, et son utilisation dans le traitement de la douleur.
MA31553A 2006-06-08 2009-01-06 Carboxamides substitues MA30620B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81183906P 2006-06-08 2006-06-08

Publications (1)

Publication Number Publication Date
MA30620B1 true MA30620B1 (fr) 2009-08-03

Family

ID=39673278

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31553A MA30620B1 (fr) 2006-06-08 2009-01-06 Carboxamides substitues

Country Status (31)

Country Link
US (1) US7960419B2 (fr)
EP (1) EP2076502B1 (fr)
JP (1) JP5108878B2 (fr)
KR (1) KR101051559B1 (fr)
CN (1) CN101466691B (fr)
AT (1) ATE509921T1 (fr)
AU (1) AU2007347428B2 (fr)
BR (1) BRPI0712862A2 (fr)
CA (1) CA2652074C (fr)
CR (1) CR10410A (fr)
CY (1) CY1111588T1 (fr)
DK (1) DK2076502T3 (fr)
EA (1) EA014233B1 (fr)
EC (1) ECSP088939A (fr)
ES (1) ES2362949T3 (fr)
HK (1) HK1131984A1 (fr)
HR (1) HRP20110436T1 (fr)
IL (1) IL195632A (fr)
MA (1) MA30620B1 (fr)
MX (1) MX2008015485A (fr)
MY (1) MY148084A (fr)
NO (1) NO341474B1 (fr)
NZ (1) NZ573352A (fr)
PL (1) PL2076502T3 (fr)
PT (1) PT2076502E (fr)
RS (1) RS51818B (fr)
SI (1) SI2076502T1 (fr)
TN (1) TNSN08506A1 (fr)
UA (1) UA95480C2 (fr)
WO (1) WO2008103185A2 (fr)
ZA (1) ZA200809111B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0804685D0 (en) 2008-03-13 2008-04-16 Univ Edinburgh Therapeutic compounds and their use
PL2276759T3 (pl) 2008-04-04 2012-03-30 Lilly Co Eli 3-indazolilo-4-pirydyloizotiazole
WO2010146338A1 (fr) * 2009-06-15 2010-12-23 The University Of Edinburgh Composés amido-isothiazole et leur utilisation comme inhibiteurs de la 11 β-hsd1 dans le traitement du syndrome métabolique et des troubles apparentés
ES2540547T3 (es) 2009-09-16 2015-07-10 The University Of Edinburgh Compuestos de (4-fenil-piperidin-1-il)-[5-(1H-pirazol-4-il)-tiofen-3-il]-metanona y su uso
DK2563780T3 (en) 2010-04-29 2015-07-27 Univ Edinburgh 3,3-DISUBSTITUEREDE- (8-aza-bicyclo [3.2.1] oct-8-yl) - [5- (1H-pyrazol-4-yl) -thiophene-3-yl] -METHANONER as inhibitors of 11 ( BETA) -HSD1
NO2921489T3 (fr) 2012-11-13 2018-02-03
JP2019529452A (ja) 2016-09-23 2019-10-17 バイエル・アクチエンゲゼルシヤフト Ｎ３−環状置換チエノウラシルおよびその使用
CN117567266B (zh) * 2023-11-07 2024-06-14 康龙化成手性医药技术(宁波)有限公司 一种制备2-甲基环丙羧酸的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL72091A0 (en) * 1983-06-20 1984-10-31 Lilly Co Eli N'-substituted(3-aryl 5-isothiazolyl)urea derivatives
DE4328425A1 (de) 1993-08-24 1995-03-02 Basf Ag Acylamino-substituierte Isoxazol- bzw. Isothiazolderivate, Verfahren zu deren Herstellung und ihre Verwendung
DK124393D0 (da) * 1993-11-03 1993-11-03 Lundbeck & Co As H Compounds
DE19542372A1 (de) * 1995-11-14 1997-05-15 Bayer Ag Acylierte 5-Aminoisothiazole
UA60365C2 (uk) * 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
JP3411262B2 (ja) * 1999-08-20 2003-05-26 萬有製薬株式会社 新規スピロ化合物
EP1435948A1 (fr) * 2001-08-06 2004-07-14 Pharmacia Italia S.p.A. D riv s d'aminoisoxazole agissant comme inhibiteurs de la kinase
EP1667983A4 (fr) * 2003-09-23 2010-07-21 Merck Sharp & Dohme Modulateurs pyrazole de recepteurs de glutamate metabotropiques
CN1984899B (zh) * 2004-05-12 2011-07-27 先灵公司 Cxcr1和cxcr2趋化因子拮抗剂
BRPI0515571A (pt) * 2004-09-23 2008-07-29 Pfizer Prod Inc agonistas de receptor de trombopoetina

Also Published As

Publication number Publication date
JP2009539874A (ja) 2009-11-19
UA95480C2 (uk) 2011-08-10
ATE509921T1 (de) 2011-06-15
ECSP088939A (es) 2009-01-30
ES2362949T3 (es) 2011-07-15
PT2076502E (pt) 2011-06-07
CA2652074C (fr) 2013-08-06
CR10410A (es) 2008-11-28
MX2008015485A (es) 2009-03-06
HK1131984A1 (en) 2010-02-12
WO2008103185A2 (fr) 2008-08-28
NZ573352A (en) 2011-10-28
NO20085028L (no) 2008-12-02
EP2076502B1 (fr) 2011-05-18
NO341474B1 (no) 2017-11-27
US20090182025A1 (en) 2009-07-16
RS51818B (en) 2011-12-31
PL2076502T3 (pl) 2011-09-30
IL195632A0 (en) 2009-09-01
AU2007347428B2 (en) 2012-02-09
DK2076502T3 (da) 2011-07-25
CN101466691A (zh) 2009-06-24
EA200870516A1 (ru) 2009-06-30
MY148084A (en) 2013-02-28
CA2652074A1 (fr) 2008-08-28
IL195632A (en) 2013-11-28
WO2008103185A3 (fr) 2008-10-30
HRP20110436T1 (hr) 2011-08-31
TNSN08506A1 (en) 2010-04-14
EA014233B1 (ru) 2010-10-29
CN101466691B (zh) 2011-07-27
CY1111588T1 (el) 2015-10-07
SI2076502T1 (sl) 2011-09-30
AU2007347428A1 (en) 2008-08-28
BRPI0712862A2 (pt) 2012-12-18
KR20090008460A (ko) 2009-01-21
US7960419B2 (en) 2011-06-14
KR101051559B1 (ko) 2011-07-22
EP2076502A2 (fr) 2009-07-08
ZA200809111B (en) 2009-12-30
JP5108878B2 (ja) 2012-12-26

Similar Documents

Publication Publication Date Title
MA30620B1 (fr) Carboxamides substitues
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
EA201071038A1 (ru) Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
EA200870216A1 (ru) Амидо соединения и их применение в качестве лекарственных средств
MX338338B (es) Composiciones y metodos utiles para el tratamiento de enfermedades respiratorias.
WO2008130320A3 (fr) Nouveaux composés 806
RS54707B1 (en) TREATMENT OF CROWN LAKVINIMOD DISEASE
TW201000473A (en) Benzene or thiophene derivative and use thereof as VAP-1 inhibitor
EA200971107A1 (ru) Катехоламиновые производные, полезные для лечения болезни паркинсона
DK1973540T3 (da) Anvendelse af benzokondenserede heterocycliske sulfamidderivater til behandling af smerte
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
ATE412636T1 (de) Piperazinylpyridinderivate als mittel gegen adipositas
CL2007000918A1 (es) Compuestos derivados de enfumafungina, inhibidores de (1,3)-beta-d-glucanosintetasa; composicion farmaceutica; y uso para tratar una infeccion fungica.
EA201000391A1 (ru) Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция
MX2009005798A (es) Recuperacion de apoplejia.
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
EA201000392A1 (ru) Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция
UA112418C2 (uk) Терапевтичний болезаспокійливий засіб
ATE468852T1 (de) Lofexidine zur intraspinalen anwendung
DOP2008000064A (es) Carboxamidas sustituidas.
EA200701086A1 (ru) Производные изоксазола, их фармацевтические композиции и способ лечения невропатической боли
UA103767C2 (ru) Карбоксамидные соединения для лечения метаболических расстройств